Skip to main content

Table 1 The expression of CCR9 in cancer patients

From: CCR9 in cancer: oncogenic role and therapeutic targeting

Tumors Cell type Methods Expression References
T-ALL PBMCs (n = 21) FCM 91.9 % [25]
Melanoma Circulating tumor cells (n = 21) FCM 57 % [58]
Melanoma Primary specimens (n = 32) IHC 69.7 % [59]
Melanoma metastasis Small intestinal metastases (n = 102) QPCR 86 % [30]
Mediastinal large B cell lymphomas Lymphoid tissue (n = 22) IHC 90.9 %a [60]
Large B cell lymphoma Gastric extranodal diffuse lymphoma (n = 10) IHC 58.33 % [61]
Large B cell lymphoma Gastrointestinal lymphoma (n = 41) IHC 66 %b [62]
Ovarian cancer Cancer tissues (n = 43) IHC Significantly higher [11]
Lung cancer Lung biopsies (n = 50) WB 1.2c [63]
Hepatocellular carcinoma Cancer tissues (n = 240) IHC 55.8 % [9]
Breast cancer Moderately differentiated cancer tissues (n = 18) IHC 50 % [64]
Poorly differentiated cancer tissues (n = 18) IHC >75 %
Colon cancer Adenomatous foci (n = 46) IHC 2.26 ± 0.06d [65]
Nasopharyngeal carcinoma Carcinoma tissues (n = 42) IHC 80.95 % [66]
  1. FCM flow cytometry, PBMC peripheral blood mononuclear cell, QPCR quantitative polymerase chain reaction, IHC immunohistochemistry, WB western blot
  2. aProportion of positive tumor cells >50 % (20/22)
  3. b3+ CCR9 staining
  4. cControl tissue (n = 50), CCR9/β-actin <0.3
  5. dNormal colon epithelium had a mean staining intensity of 1.60 ± 0.04 (n = 55)